NL- Gilde and Van Herk Groep support third financing round for Agendia

Van Herk Group and Gilde Healthcare have provided third round financing to Dutch biotech company Agendia BV. The funds raised will be used to accelerate development of microarray-based late stage products into diagnostic tests for breast cancer and other cancer types and to globally market the lead products, MammaPrint® and CupPrint®. Besides the above two investors, investors in Agendia BV include AXA Private Equity Venture Funds, Global Life Sciences Ventures and the Netherlands Cancer Institute (NKI).